PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Summary

This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET/MRI, 18F-FDG PET/CT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.

Conditions

• Acute Myeloid Leukemia
• Acute Promyelocytic Leukemia With PML-RARA

Interventions

PROCEDURE

Computed Tomography

Undergo 18F-FDG PET/CT

PROCEDURE

Diffusion Weighted Imaging

Undergo whole body PET/MRI

RADIATION

Fludeoxyglucose F-18

Undergo 18F-FDG PET/CT

DRUG

Gadolinium

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo whole body PET/MRI

PROCEDURE

Positron Emission Tomography

Undergo 18F-FDG PET/CT and whole body PET/MRI

PROCEDURE

Three-Dimensional Spoiled Gradient MRI

Undergo whole body PET/MRI

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• Dawid Schellingerhout · M.D. Anderson Cancer Center

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-15

Primary Completion

2027-09-15

Completion

2027-09-15

FDA Drug

Yes

Countries

• United States

Study Locations